1.
David CH,
Carl JD.
et al. Findings of the UK National Audit Evaluating Image-guided or Image-assisted Liver Biopsy.
Part II.
Minor and Major Complications and Procedure-related Mortality. Radiology 2013; 266: 226-235
2.
Sandrasegaran K,
Faith M,
et al. Value of Diffusion-Weighted MRI for Assessing Liver Fibrosis and Cirrhosis. AJR 2009; 193:1556–1560
3.
Lewin M,
Poujol RA,
et al. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis.
CHEPATOLOGY 2007;46:658-665.
4.
Luciani A, Vignaud A, et al. Liver Cirrhosis: Intravoxel Incoherent Motion MR Imaging—Pilot Study. Radiology 2008; 249: 891-899
5.
Tschirch FT,
Struwe A,
et al. Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol.
2008 Aug;18(8):1577-86
6.
Nojiri S,
Kusakabe A,
et al. Noninvasive evaluation of hepatic fibrosis in hepatitis C virus-infected patients using ethoxybenzyl-magnetic resonance imaging. J GH. 2013 June;28(6):1032-1039
7.
Goshima S,
Kanematsu M,
et al. Gd-EOB-DTPA-enhanced MR imaging: prediction of hepatic fibrosis stages using liver contrast enhancement index and liver-to-spleen volumetric ratio. J Magn Reson Imaging.
2012 Nov;36(5):1148-53.
8.Bakan AA, Inci E, et al. Utility of diffusion-weighted imaging in the evaluation of liver fibrosis.
Eur Radiol 2012; 22:682–687.
9.Boulanger Y,
Amara M,
et al. Diffusion-weighted MR imaging of the liver of hepatitis C patients. NMR Biomed.
2003;16:132–136.
10.Hollingsworth KG,
Lomas DJ,
et al. Influence of perfusion on hepatic MR diffusion measurement. NMR Biomed.
2006; 19:231–235
11. Poyraz AK,
Onur MR, et al. Diffusion-weighted MRI of fatty liver.
JMRI 2012; 35(5): 1108-11.